Vaxcyte, Inc. (PCVX) Free cash flow 2018–2025
Vaxcyte, Inc. (PCVX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$669.3MFY2025 · since FY2018: -$32.2M → -$669.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$669.3M | -40.9% |
| FY2024 | -$475.1M | -51.8% |
| FY2023 | -$312.9M | -77.3% |
| FY2022 | -$176.4M | -37.9% |
| FY2021 | -$127.9M | -167.8% |
| FY2020 | -$47.8M | +1.2% |
| FY2019 | -$48.3M | -49.9% |
| FY2018 | -$32.2M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More PCVX financial trends
PCVX RevenuePCVX Net incomePCVX Net marginPCVX Gross profitPCVX Gross marginPCVX Operating incomePCVX Operating marginPCVX Operating cash flowPCVX Capital expendituresPCVX Return on equityPCVX Stock buybacksPCVX Dividends paidPCVX Total assetsPCVX Total liabilitiesPCVX Shareholders’ equityPCVX overview →